Big Pharma is investing heavily in AI to slash development timelines and foster innovation. But instead of strengthening future relationships with the biotech world, the investment may position ...
This article has been revised and corrected from the original version. A new lender has emerged on the Los Angeles scene – one specifically targeting established life science companies. Symbiotic is ...
A new global life science credit firm, dubbed Symbiotic Capital, has raised more than $600 million. Symbiotic will deliver credit solutions to companies across biotech, medtech, synthetic biology and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback